EBS Valuation

Emergent BioSolutions Inc

Add to Watchlist

Advanced Chart

6.930

-0.35(-4.808%)1D

Overview
Forecast
Valuation
Earnings

EBS Relative Valuation

EBS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EBS is overvalued; if below, it's undervalued.

Historical Valuation

Emergent BioSolutions Inc (EBS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.45 is considered Undervalued compared with the five-year average of 14.70. The fair price of Emergent BioSolutions Inc (EBS) is between 27.03 to 50.82 according to relative valuation methord. Compared to the current price of 6.93 USD , Emergent BioSolutions Inc is Undervalued By 74.36%.

Relative Value

Fair Zone

27.03-50.82

Current Price：6.93

74.36%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.68

P/B

Median3y

0.59

Median5y

1.37

23.89

FCF Yield

Median3y

-50.96

Median5y

-28.39

Competitors Valuation Multiple

The average P/S ratio for EBS's competitors is 7.08, providing a benchmark for relative valuation. Emergent BioSolutions Inc Corp (EBS) exhibits a P/S ratio of 0.45, which is -93.67% above the industry average. Given its robust revenue growth of -26.03%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

EBS.N

Emergent BioSolutions Inc

0.45

Average P/S: 7.08

-26.03%